The second half of 2021 remains the target for the completion of the recruitment of the pivotal phase 3 trial sponsored by GlycoMimetics evaluating uproleselan in patients with relapsing / refractory acute myeloid leukemia (AML)
Enrollment in 2021 is expected to support a planned interim analysis based on event-free survival in the National Cancer Institute (NCI) registration trial evaluating uproleselan in newly diagnosed AML patients over the age of 60 and suitable for chemotherapy.
The Company announces its intention to advance GMI-1687 to an Investigational New Drug Repository (IND), with the acute treatment of acute outpatient vaso-occlusive crisis (VOC) as a possible use. The company stops the development of rivipansel
Evidence of biological activity in the first patients treated in the Phase 1b study of GMI-1359 in advanced breast cancer has been submitted to a scientific meeting for presentation.
Set up a conference call and webcast today at 8:30 a.m.ET
GlycoMimetics, Inc. (Nasdaq: GLYC) today released its financial results for the fourth quarter and fiscal year ended December 31, 2020, and highlighted recent company events, including several accomplishments reported to date in 2021. Cash and cash equivalents as of December 31, 2020 was $ 137.0 million.
“In 2020, we remained on track to complete the recruitment of our uproleselan pivotal trial in the second half of 2021. Uproleselan continues to enjoy strong support from collaborators working with us in the clinical and preclinical areas. We…
News Highlights Finance
- Headline: GlycoMimetics Releases Fourth Quarter and Full Year 2020 Highlights and Financial Results
- Check all news and articles from the Finance news updates.